BH3 Mimetics: Status of the Field and New Developments
Christian Billard

Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma

AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo

Smac Mimetics in Combination with TRAIL Selectively Target Cancer Stem Cells in Nasopharyngeal Carcinoma
Man-si Wu, Guang-feng Wang, Zhi-qiang Zhao, Yi Liang, Heng-bang Wang, Miao-yi Wu, Ping Min, Li-zhen Chen, Qi-sheng Feng, Jin-xin Bei, Yi-xin Zeng, and Da-jun Yang

Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTEN11-Associated Malignancies

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro
Jinsong Hu, Els Van Valkenborgh, Dehui Xu, Eline Menu, Hendrik De Raeve, Elke De Bryune, Song Xu, Ben Van Camp, Damian Handisides, Charles P. Hart, and Karin Vanderkerken

S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Mike F. Burbridge, Céline J. Bossard, Carine Saunier, Imre Fejes, Alain Bruno, Stéphane Leonce, Gilles Ferry, Georges Da Violante, François Bouzom, Valérie Cattan, Anne Jacquet-Bescond, Paolo M. Comoglio, Brian P. Lockhart, Jean A. Boutin, Alex Cordi, Jean-Claude Ortuno, Alain Pierré, John A. Hickman, Francisco H. Cruzalegui, and Stéphane Depil

Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302

Targeted Cytolysins Synergistically Potentiate Cytoplasmic Delivery of Gelonin Immunotoxin
Christopher M. Pirie, David V. Liu, and K. Dane Wittrup

Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells

Cyclin G1 Expands Liver Tumor-Initiating Cells by Sox2 Induction via Akt/mTOR Signaling
Ren Wei, Tao Han, Cheng Chen, Lei Huang, Wen Sun, Xue Wang, Shu-Zhen Chen, Dai-Min Xiang, Liang Tang, Dan Cao, Gen-Sheng Feng, Meng-Chao Wu, Jin Ding, and Hong-Yang Wang
1805  **An Autocrine Loop between TGF-β1 and the Transcription Factor Brachyury Controls the Transition of Human Carcinoma Cells into a Mesenchymal Phenotype**  Cecilia Larocca, Joseph R. Cohen, Romaine I. Fernando, Bruce Huang, Duane H. Hamilton, and Claudia Palena

1816  **Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect**  Bart S. Hendriks, Stephan G. Klinz, Joseph G. Reynolds, Christopher W. Espelin, Daniel F. Gaddy, and Thomas J. Wickham

1829  **Inhibition of ABCB1 Expression Overcomes Acquired Docetaxel Resistance in Prostate Cancer**  Yezi Zhu, Chengfei Liu, Nagalakshmi Nadiminty, Wei Lou, Ramakumar Tummala, Christopher P. Evans, and Allen C. Gao

1837  **Ethacrynic Acid Oxadiazole Analogs Induce Apoptosis in Malignant Hematologic Cells through Downregulation of Mcl-1 and c-FLIP, Which Was Attenuated by GSTP1-1**  Guyue Liu, Rui Wang, Yuetong Wang, Pengzhan Li, Guisen Zhao, Linxiang Zhao, and Yongkui Jing

1848  **Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin Signaling**  Nan Li, Yaguang Xi, Heather N. Tinsley, Evrim Gurpinar, Bernard D. Gary, Bing Zhu, Yonghe Li, Xi Chen, Adam B. Keeton, Ashraf H. Abadi, Mary P. Moyer, William E. Grizzle, Sanjiv S. Gambhir

1860  **Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53**  Mayur A. Gadhikar, Maria Rita Sciuto, Marcus Vinicius Ortega Alves, Curtis R. Pickering, Abdulllah A. Osman, David M. Neskey, Mei Zhao, Alison L. Fitzgerald, Jeffrey N. Myers, and Mitchell J. Frederick


1886  **Apoptotic Circulating Tumor Cells in Early and Metastatic Breast Cancer Patients**  Galatea Kallergi, Georgios Konstantinidis, Harris Markomanolaki, Maria A. Papadaki, Dimitris Mavroudis, Christos Stournaras, Vassilis Georgoulis, and Sofia Angelaki

1896  **A c-Myc Activation Sensor-Based High-Throughput Drug Screening Identifies an Antineoplastic Effect of Nitazoxanide**  Hua Fan-Minogue, Sandhya Bodapati, David Solow-Cordero, Alice Fan, Ramasamy Paulmurugan, Tarik F. Massoud, Dean W. Felsher, and Sanjiv S. Gambhir

1906  **NF1 Deletion Generates Multiple Subtypes of Soft-Tissue Sarcoma That Respond to MEK Inhibition**  Rebecca D. Dodd, Jeffrey K. Mito, William C. Eward, Rhea Chitalia, Mohit Sachdeva, Yan Ma, Jordi Barretina, Leslie Dodd, and David G. Kirsch

1918  **O. Michael Colvin, MD: In Memoriam (1936–2013)**

1919  **Correction: MPT0B098, a Novel Microtubule Inhibitor That Destabilizes the Hypoxia-Inducible Factor-1α mRNA through Decreasing Nuclear–Cytoplasmic Translation of RNA-Binding Protein HuR**  Yun-Ching Cheng, Jing-Ping Liu, Ching-Chuan Kuo, Wen-Yang Lai, Kuang-Hsing Shih, Chi-Yen Chang, Wen-Yu Pan, Joseph T. Tseng, and Jang-Yang Chang
Correction: Dual Programmed Cell Death Pathways Induced by p53 Transactivation Overcome Resistance to Oncolytic Adenovirus in Human Osteosarcoma Cells

ABOUT THE COVER

Continued androgen receptor (AR) expression and signaling is a key driver in castration-resistant prostate cancer (CRPC). AZD3514 is an orally bioavailable drug that inhibits androgen-dependent and -independent AR signalling in vitro and in vivo. Using immunohistochemistry, R3327H prostate tumors were scored for intensity of nuclear AR to assess the impact of AZD3514 on AR. For more details, see article by Loddick and colleagues on page 1715.